Huang X - Search Results

1

Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus Recommendations.

Meric-Bernstam F, Lloyd MW, Koc S, Evrard YA, McShane LM, Lewis MT, Evans KW, Li D, Rubinstein LV, Welm AL, Dean DA, Srivastava A, Grover JW, Ha MJ, Chen H, Huang X, Varadarajan K, Wang J, Roth JA, Welm BE, Govindan R, Ding L, Kaochar S, Mitsiades N, Carvajal-Carmona LG, Herlyn M, Davies MA, Shapiro GI, Fields RC, Trevino JG, Harrell JC, Doroshow JH, Chuang JH, Moscow JA. Meric-Bernstam F, et al. Among authors: huang x. Mol Cancer Ther. 2024 Apr 20. doi: 10.1158/1535-7163.MCT-23-0471. Online ahead of print. Mol Cancer Ther. 2024. PMID: 38641411

2

BH3 profiling discriminates response to cytarabine-based treatment of acute myelogenous leukemia.

Pierceall WE, Kornblau SM, Carlson NE, Huang X, Blake N, Lena R, Elashoff M, Konopleva M, Cardone MH, Andreeff M. Pierceall WE, et al. Among authors: huang x. Mol Cancer Ther. 2013 Dec;12(12):2940-9. doi: 10.1158/1535-7163.MCT-13-0692. Epub 2013 Oct 3. Mol Cancer Ther. 2013. PMID: 24092807 Free PMC article.

3

Metastatic melanoma to lymph nodes in patients with unknown primary sites.

Cormier JN, Xing Y, Feng L, Huang X, Davidson L, Gershenwald JE, Lee JE, Mansfield PF, Ross MI. Cormier JN, et al. Among authors: huang x. Cancer. 2006 May 1;106(9):2012-20. doi: 10.1002/cncr.21835. Cancer. 2006. PMID: 16568458 Free article.

4

Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience.

Kantarjian HM, O'Brien S, Huang X, Garcia-Manero G, Ravandi F, Cortes J, Shan J, Davisson J, Bueso-Ramos CE, Issa JP. Kantarjian HM, et al. Among authors: huang x. Cancer. 2007 Mar 15;109(6):1133-7. doi: 10.1002/cncr.22508. Cancer. 2007. PMID: 17315156 Free PMC article. Clinical Trial.

5

Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype.

Konoplev S, Rassidakis GZ, Estey E, Kantarjian H, Liakou CI, Huang X, Xiao L, Andreeff M, Konopleva M, Medeiros LJ. Konoplev S, et al. Among authors: huang x. Cancer. 2007 Mar 15;109(6):1152-6. doi: 10.1002/cncr.22510. Cancer. 2007. PMID: 17315232 Free article.

6

Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?

Kantarjian H, O'Brien S, Shan J, Huang X, Garcia-Manero G, Faderl S, Ravandi-Kashani F, Verstovsek S, Beth Rios M, Cortes J. Kantarjian H, et al. Among authors: huang x. Cancer. 2008 Feb 15;112(4):837-45. doi: 10.1002/cncr.23238. Cancer. 2008. PMID: 18085610 Free article.

7

Adjuvant high-dose interferon for cutaneous melanoma is most beneficial for patients with early stage III disease.

Anaya DA, Xing Y, Feng L, Huang X, Camacho LH, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Cormier JN. Anaya DA, et al. Among authors: huang x. Cancer. 2008 May 1;112(9):2030-7. doi: 10.1002/cncr.23399. Cancer. 2008. PMID: 18320602 Free PMC article.

8

Cytoplasmic localization of nucleophosmin in bone marrow blasts of acute myeloid leukemia patients is not completely concordant with NPM1 mutation and is not predictive of prognosis.

Konoplev S, Huang X, Drabkin HA, Koeppen H, Jones D, Kantarjian HM, Garcia-Manero G, Chen W, Medeiros LJ, Bueso-Ramos CE. Konoplev S, et al. Among authors: huang x. Cancer. 2009 Oct 15;115(20):4737-44. doi: 10.1002/cncr.24543. Cancer. 2009. PMID: 19637342 Free PMC article.

9

Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients.

Faderl S, Ravandi F, Huang X, Wang X, Jabbour E, Garcia-Manero G, Kadia T, Ferrajoli A, Konopleva M, Borthakur G, Burger J, Feliu J, Kantarjian HM. Faderl S, et al. Among authors: huang x. Cancer. 2012 Sep 15;118(18):4471-7. doi: 10.1002/cncr.27429. Epub 2012 Jan 26. Cancer. 2012. PMID: 22282348 Free PMC article. Clinical Trial.

10

Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.

Huang X, Cortes J, Kantarjian H. Huang X, et al. Cancer. 2012 Jun 15;118(12):3123-7. doi: 10.1002/cncr.26679. Epub 2012 Jan 31. Cancer. 2012. PMID: 22294282 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

43,912 results

Search Page